As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a
most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma …

Tyrosine kinase inhibitors (TKIs) are currently used by most oncologists. Among their side
effects, thyroid dysfunctions are nowadays clearly observed. Whereas changes in thyroid …

Background Pazopanib and sunitinib provided a progression-free survival benefit, as
compared with placebo or interferon, in previous phase 3 studies involving patients with …

Purpose Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial
growth factor receptor 1 (VEGFR1),-2, and-3. This phase III trial compared tivozanib with …

Background In the phase 3 KEYNOTE-426 (NCT02853331) trial, pembrolizumab+ axitinib
demonstrated improvement in overall survival, progression-free survival, and objective …

Background AGS-003 is an autologous immunotherapy prepared from fully matured and
optimized monocyte-derived dendritic cells, which are co-electroporated with amplified …

Background: Pazopanib, an oral angiogenesis inhibitor targeting vascular endothelial
growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit, is …

Context: Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal
experiments pointed toward adrenal toxicity of sunitinib. Objective: The objective of the study …

Purpose: Sarcopenia, a novel concept reflecting the degenerative loss of skeletal muscle
mass, is a critical physiological change during the development of cancer cachexia. We …

Background Previous findings showed that cediranib-olaparib increased PFS in women with
recurrent platinum-sensitive ovarian cancer compared to olaparib alone. Methods …